Immunohistochemical Marker Expression in Temporal Bone Squamous Cell Carcinoma.
Journal
The Tokai journal of experimental and clinical medicine
ISSN: 2185-2243
Titre abrégé: Tokai J Exp Clin Med
Pays: Japan
ID NLM: 7704186
Informations de publication
Date de publication:
20 Jul 2021
20 Jul 2021
Historique:
received:
27
11
2020
accepted:
05
03
2021
entrez:
3
7
2021
pubmed:
4
7
2021
medline:
29
10
2021
Statut:
epublish
Résumé
The correlation between genomic mutations (or the overexpression of abnormal proteins) and prognosis in temporal bone squamous cell carcinoma (TBSCC) is not clear. We investigated the overexpression of EGFR and p53 as a pathological biomarker for predicting the clinical course of patients with TBSCC. We performed a retrospective review of 22 TBSCC cases treated in Tokai University Hospital between January 2005 and October 2016. We assessed the overexpression of EGFR and p53 in TBSCC patients through immunohistochemical staining. We also evaluated the association between the overexpression of these proteins and clinicopathological variables, including survival outcomes. The primary lesion in all patients was the external auditory canal. Nine (40.9%) patients were EGFR positive, and 9 (40.9%) were p53 positive. The 5-year overall survival rate for EGFR-positive patients (55.6%) was significantly lower (p = 0.043) than that of the EGFR-negative patients (92.3%). EGFR overexpression in TBSCC patients may be a prognostic biomarker.
Sections du résumé
BACKGROUND
BACKGROUND
The correlation between genomic mutations (or the overexpression of abnormal proteins) and prognosis in temporal bone squamous cell carcinoma (TBSCC) is not clear. We investigated the overexpression of EGFR and p53 as a pathological biomarker for predicting the clinical course of patients with TBSCC.
METHODS
METHODS
We performed a retrospective review of 22 TBSCC cases treated in Tokai University Hospital between January 2005 and October 2016. We assessed the overexpression of EGFR and p53 in TBSCC patients through immunohistochemical staining. We also evaluated the association between the overexpression of these proteins and clinicopathological variables, including survival outcomes.
RESULTS
RESULTS
The primary lesion in all patients was the external auditory canal. Nine (40.9%) patients were EGFR positive, and 9 (40.9%) were p53 positive. The 5-year overall survival rate for EGFR-positive patients (55.6%) was significantly lower (p = 0.043) than that of the EGFR-negative patients (92.3%).
CONCLUSION
CONCLUSIONS
EGFR overexpression in TBSCC patients may be a prognostic biomarker.
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM